TP53 and cancer: In line with these findings, it has been shown that minocycline attenuates HIF-1α expression through an increase in p53 and a decrease in Akt/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer, both in vitro and in vivo, providing new insight into the discovery of drugs for cancer treatment [60].